Clinical Trial Update: The Acetylcysteine for Contrast-Induced Nephropathy Trial [Phase 3]

View source ↗

Summary

This update reports on a Phase 3 trial evaluating acetylcysteine to prevent contrast-induced nephropathy in patients at risk for acute kidney injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Acetylcysteine (Acetylcysteine)

Snippet

Sponsor: Hospital do Coracao | Conditions: Acute Kidney Failure | Phase 3 | Status: COMPLETED